摘要
目的了解江苏省徐州市丙型肝炎(简称丙肝)患者抗病毒治疗情况及当前感染状态,分析接受抗病毒治疗的影响因素。方法从中国疾病预防控制信息系统中下载2004-2020年徐州市报告所有已审核丙肝病例,进行现场问卷调查,并通过核酸检测确定其当前的感染状态。采用Pearsonχ^(2)检验和Logistic回归模型探讨影响丙肝患者接受抗病毒治疗的因素。结果本研究共调查丙肝患者1160例,其中有效问卷1106份(95.3%)且均采集到血样,接受过抗病毒治疗率为39.0%。多因素Logistic回归结果显示,曾进行丙肝核酸检测(OR=4.654,95%CI:3.573~6.061)、丙肝知识知晓(OR=1.543,95%CI:1.168~2.038)以及个人月收入>3000元(OR=1.524,95%CI:1.069~2.173)的患者接受抗病毒治疗率较高;年龄≥70岁(OR=0.601,95%CI:0.382~0.945)抗病毒治疗率较低。抗病毒治疗方案中直接抗病毒药物(DAAs)方案治愈率(93.7%)高于干扰素(IFN)方案(87.6%)。差异有统计学意义(χ^(2)=4.870,P=0.027)。结论徐州市既往丙肝患者抗病毒治疗率较低,应加强对丙肝患者的健康教育,提高抗病毒治疗覆盖率以消除丙肝公共卫生的危害。
Objective To investigate the antiviral therapy received and the current infection status of patients with hepatitis C in Xuzhou City,Jiangsu Province and to analyze the influencing factors.Methods All hepatitis C cases reported in Xuzhou from 2004 to 2020 were downloaded from the China Disease Prevention and Control Information System.A questionnaire survey was conducted on the spot.The current infection status was determined by nucleic acid detection.Pearsonχ~2 test and logistic regression model were used to investigate the factors affecting hepatitis C patients receiving antiviral therapy.Results A total of 1160 hepatitis C patients were investigated in this study,of whom 1106valid questionnaires(95.3%)and blood samples were collected.The rate of receiving antiviral therapy was 39.0%.Multivariate logistic regression showed that patients who had undergone hepatitis C nucleic acid testing(OR=4.654,95%CI:3.573-6.061),aware of hepatitis C knowledge(OR=1.543,95%CI:1.168-2.038)and personal monthly income>3000 yuan(OR=1.524,95%CI:1.069-2.173)had a higher rate of antiviral therapy.Patients aged≥70 years(OR=0.601,95%CI:0.382-0.945)had a lower rate of antiviral therapy.The cure rate by the direct antiviral drugs(DAAs)regimen(93.7%)was higher than that by the interferon(IFN)regimen(87.6%).The difference was statistically significant(χ~2=4.870,P=0.027).Conclusions The rate of antiviral therapy in patients with hepatitis C in Xuzhou is low.Health education should be strengthened for patients with hepatitis C to improve the coverage of antiviral therapy to eliminate the public health harm of hepatitis C.
作者
张钏沨
张培栋
孙传武
卢静
傅更锋
李健
羊海涛
ZHANG Chuanfeng;ZHANG Peidong;SUN Chuanwu;LU Jing;FU Gengfeng;LI Jian;YANG Haitao(Department of Epidemiology and Health Statistics,School of Public Health,Southeast University,Nanjing 210009,China;Department of HIV/AIDS/STI Prevention and Control,Xuzhou Center for Diseases Control and Prevention,Xuzhou 221000;Institute of HIV/AIDS/STI Prevention and Control,Jiangsu Provincial Center for Diseases Control and Prevention,Nanjing 210009;National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention,Beijing102200)
出处
《中国艾滋病性病》
CAS
CSCD
北大核心
2022年第12期1355-1358,共4页
Chinese Journal of Aids & STD
